First human trial on melanoma vax 'cure'

A group of researchers at Nottingham University in the U.K. are planning to launch a human trial of a new vaccine for metastatic melanoma. Lead researcher Professor Lindy Durrant says that the vaccine contains DNA and tumor fragments so that it will activate only specific immune cells rather than the entire immune system. Report

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.